scholarly journals Letter: bone fracture risk among older long-term users of proton pump inhibitors. Authors’ reply

2020 ◽  
Vol 52 (2) ◽  
pp. 408-408
Author(s):  
Felice Schnoll-Sussman ◽  
Philip O. Katz
Keyword(s):  
Fracture Risk ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Bone Fracture

scholarly journals Proton Pump Inhibitors and Fracture Risk: A Review of Current Evidence and Mechanisms Involved

2019 ◽  
Vol 16 (9) ◽  
pp. 1571 ◽  
Author(s):  
Benjamin Ka Seng Thong ◽  
Soelaiman Ima-Nirwana ◽  
Kok-Yong Chin
Keyword(s):  
Fracture Risk ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Bone Health ◽  
Current Evidence ◽  
Mineral Absorption ◽  
Number Of Patients ◽  
The Relationship ◽  
Fracture Risks

The number of patients with gastroesophageal problems taking proton pump inhibitors (PPIs) is increasing. Several studies suggested a possible association between PPIs and fracture risk, especially hip fractures, but the relationship remains contentious. This review aimed to investigate the longitudinal studies published in the last five years on the relationship between PPIs and fracture risk. The mechanism underlying this relationship was also explored. Overall, PPIs were positively associated with elevated fracture risk in multiple studies (n = 14), although some studies reported no significant relationship (n = 4). Increased gastrin production and hypochlorhydria are the two main mechanisms that affect bone remodeling, mineral absorption, and muscle strength, contributing to increased fracture risk among PPI users. As a conclusion, there is a potential relationship between PPIs and fracture risks. Therefore, patients on long-term PPI treatment should pay attention to bone health status and consider prophylaxis to decrease fracture risk.

scholarly journals Hypomagnesemia Induced by Long-Term Treatment with Proton-Pump Inhibitors

2015 ◽  
Vol 2015 ◽  
pp. 1-7 ◽  
Author(s):  
Simone Janett ◽  
Pietro Camozzi ◽  
Gabriëlla G. A. M. Peeters ◽  
Sebastiano A. G. Lava ◽  
Giacomo D. Simonetti ◽  
...  
Keyword(s):  
Receptor Antagonist ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Term Treatment ◽  
Cross Sectional ◽  
Magnesium Metabolism ◽  
Poor Renal Function ◽  
Long Term Treatment

In 2006, hypomagnesemia was first described as a complication of proton-pump inhibitors. To address this issue, we systematically reviewed the literature. Hypomagnesemia, mostly associated with hypocalcemic hypoparathyroidism and hypokalemia, was reported in 64 individuals on long-term proton-pump inhibitors. Hypomagnesemia recurred following replacement of one proton-pump inhibitor with another but not with a histamine type-2 receptor antagonist. The association between proton-pump inhibitors and magnesium metabolism was addressed in 14 case-control, cross-sectional studies. An association was found in 11 of them: 6 reports found that the use of proton-pump inhibitors is associated per se with a tendency towards hypomagnesemia, 2 found that this tendency is more pronounced in patients concurrently treated with diuretics, carboplatin, or cisplatin, and 2 found a relevant tendency to hypomagnesemia in patients with poor renal function. Finally, findings likely reflecting decreased intestinal magnesium uptake were observed on treatment with proton-pump inhibitors. Three studies did not disclose any relationship between magnesium metabolism and treatment with histamine type-2 receptor antagonists. In conclusion, proton-pump inhibitors may cause hypomagnesemia. In these cases, switching to a histamine type-2 receptor antagonist is advised.

The effects of long-term therapy with proton pump inhibitors on meal stimulated gastrin

2014 ◽  
Vol 46 (2) ◽  
pp. 125-130 ◽  
Author(s):  
Hólmfridur Helgadóttir ◽  
David C. Metz ◽  
Yu-Xiao Yang ◽  
Andrew D. Rhim ◽  
Einar S. Björnsson
Keyword(s):  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Term Therapy ◽  
Long Term Therapy
Sign in / Sign up

Export Citation Format

Share Document